Despite promising results in the preclinical setting, where anti-FAP antibodies reduced tumor growth [99] and overcame resistance to chemotherapy in animal models [101], these strategies failed in early phase II studies due to limited ability of the sole anti-FAP antibody of reducing metastatic colorectal cancer burden in patients [102]. Here, FAP is linked to neoplasm.